Cubist Pharmaceuticals, Inc. Enrolls 1st Patient in Phase 3 Trial for Therapy to Treat Clostridium Difficile-Associated Diarrhea

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of its pivotal Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, or CDAD, with enrollment of a patient in the first of two planned identical global trials. These are randomized, double-blind, global studies in which CB-315 (250 mg BID) is being compared with the active comparator oral vancomycin (125 mg QID). Each trial is expected to enroll 608 eligible patients.

Back to news